David G Bostwick1, Isabelle Meiers. 1. Bostwick Laboratories, 4355 Innslake Dr, Glen Allen, VA 23060, USA. mmcdonald@bostwicklaboratories.com
Abstract
CONTEXT: Prostate cancer is the most common cancer of men in the United States and is third only to lung and colon cancer as a cause of cancer death. In 2006, 27,350 Americans will die of prostate cancer, and 234,460 new cases will be diagnosed. Treatment changes in the benign and cancerous prostate create diagnostic challenges in pathologic interpretation, particularly in needle biopsy specimens and in evaluation of extraprostatic metastases. OBJECTIVE: To summarize therapy-related pathologic findings in the prostate with emphasis on recognition of treated adenocarcinoma. DATA SOURCES: Extensive review of published literature and the authors' experience. CONCLUSIONS: Following therapy for prostate cancer, it is critical that the clinician provide the pertinent history of androgen deprivation or radiation therapy to assist the pathologist in rendering the correct diagnosis.
CONTEXT: Prostate cancer is the most common cancer of men in the United States and is third only to lung and colon cancer as a cause of cancer death. In 2006, 27,350 Americans will die of prostate cancer, and 234,460 new cases will be diagnosed. Treatment changes in the benign and cancerous prostate create diagnostic challenges in pathologic interpretation, particularly in needle biopsy specimens and in evaluation of extraprostatic metastases. OBJECTIVE: To summarize therapy-related pathologic findings in the prostate with emphasis on recognition of treated adenocarcinoma. DATA SOURCES: Extensive review of published literature and the authors' experience. CONCLUSIONS: Following therapy for prostate cancer, it is critical that the clinician provide the pertinent history of androgen deprivation or radiation therapy to assist the pathologist in rendering the correct diagnosis.
Authors: Michele Billia; Khurram M Siddiqui; Susanne Chan; Fan Li; Ali Al-Zahrani; Jose A Gomez; Joseph L Chin Journal: Can Urol Assoc J Date: 2016 Nov-Dec Impact factor: 1.862
Authors: Himisha Beltran; Alexander W Wyatt; Edmund C Chedgy; Adam Donoghue; Matti Annala; Evan W Warner; Kevin Beja; Michael Sigouros; Fan Mo; Ladan Fazli; Colin C Collins; James Eastham; Michael Morris; Mary-Ellen Taplin; Andrea Sboner; Susan Halabi; Martin E Gleave Journal: Clin Cancer Res Date: 2017-08-25 Impact factor: 12.531
Authors: B Walter; T Weiss; F Hofstädter; A Gaumann; A Hartmann; S Rogenhofer; R Ganzer; S Wach; D Engehausen; W F Wieland; A Blana Journal: World J Urol Date: 2012-02-19 Impact factor: 4.226
Authors: Wolfgang P Fendler; Jeremie Calais; Matthias Eiber; Jeffrey P Simko; John Kurhanewicz; Romelyn Delos Santos; Felix Y Feng; Robert E Reiter; Matthew B Rettig; Nicholas G Nickols; Amar U Kishan; Roger Slavik; Peter R Carroll; Courtney Lawhn-Heath; Ken Herrmann; Johannes Czernin; Thomas A Hope Journal: Eur J Nucl Med Mol Imaging Date: 2020-08-17 Impact factor: 9.236
Authors: Arnas Rakauskas; Taimur T Shah; Max Peters; Jagpal S Randeva; Feargus Hosking-Jervis; Michael J Schmainda; Clement Orczyck; Mark Emberton; Manit Arya; Caroline Moore; Hashim U Ahmed Journal: Urol Oncol Date: 2021-05-26 Impact factor: 3.498